<DOC>
	<DOCNO>NCT02909361</DOCNO>
	<brief_summary>Fulvestrant 500mg Patients With Advanced Breast Cancer</brief_summary>
	<brief_title>Fulvestrant 500mg Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>A multicenter , prospective study real-world evaluate safety profile effectiveness Chinese patient receive Fulvestrant 500mg first-line endocrine treatment Advanced breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Chinese woman estrogen receptor positive , locally advanced metastatic breast cancer already receive Fulvestant 500mg treatment determine treat physician . Ovarian suppression premenopausal woman permit , include ovarian ablation LHRHa . 2 . Histologically confirm positive oestrogen receptor status ( ER positive ) primary breast cancer metastatic tumour tissue , accord local laboratory parameter . 3 . Prior endocrine therapy advance disease permit . 4 . The prescription Fulvestant clearly separate decision include subject NIS , part normal medical practice . The recruitment patient study within 1 month first Fulvestant injection . 5 . Provision subject inform consent . 1 . If participate control clinical trial , subject take part study . 2 . HER2 overexpression gene amplification , ie , immunohistochemistry ( IHC ) 3+ fluorescence situ hybridisation ( FISH ) + , appropriate . 3 . Pervious regimen endocrine therapy advanced disease . 4 . More one regimen chemotherapy advance disease . 5 . Pregnancy lactation . 6 . Severe hepatic impairment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>